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ABSTRACT Presented herein is a clinical study comprising 48 patients (42 men and 6 women) of working age 
(40–70 years), all of whom are suffering from locally advanced oropharyngeal cancer. A modern approach is 
applied to treat these patients, i.e., neoadjuvant targeted therapy, taking into account the biological profile of 
the tumor. The use of gefitinib causes an antitumor effect in 90.5% of cases as opposed to 56.5% when no drug is 
applied.
KEYWORDS oropharyngeal cancers; targeted therapy; quality of life; gefitinib.
ABBREVIATIONS SCCHN – squamous-cell carcinoma of the head and neck; EGFR – epidermal growth factor 
receptor.
INTRODUCTION
Malignant tumors of the head and neck account for 
20% of overall incidences of cancer. Squamous-cell 
carcinoma of the head and neck (SccHn) is one of the 
most frequently observed types among other malig-
nant tumors, the number of cases exceeding 600,000 
annually [1]. In russia, more than 80,000 patients with 
the pathology are registered every year; 3.5% of them 
are patients suffering from cancer of the mouth and 
throat. In the territory of the russian Federation, the 
incidence of oropharyngeal cancers increased from 24.7 
to 29.6 per 100,000 for the period from 1997 to 2007. In 
more than 70% of the cases, patients seek medical care 
when the disease is advanced (stages III, IV); in these 
stages, radical surgery is either impossible or severely 
restricted [1, 2]. the percentage of advanced oropha-
ryngeal cancer cases has risen from 26.4 to 31.2%; the 
mortality rate from this is 15.6% [3]. the severity and 
urgency of this problem is beyond question, since the 
problem affects people of working age.
using surgical intervention for patients of this group 
involves performing extended and combined surgeries, 
which have a mutilating effect, thereby significantly 
impairing the quality of life. radiation therapy, either 
in combination with surgical treatment or alone at high 
doses of radiation, causes the development of severe 
complications (xerostomia, dysphagia, mucositis, etc.), 
which significantly limit its application, and impair psy-
chosocial adaptation and rehabilitation of the patients.
In addition, during combined therapy, local recur-
rence occurs in 10–30% of patients with SccHn, in-
cluding those with histologically normal resection 
margins; the latter indicates a probable subclinical sys-
temic extension of the tumor, occurring even prior to 
the stage of generalization. In this context, the complex 
approach plays an increasingly important role not only 
in surgery and radiation therapy, but in medicamental 
treatment as well; in other words, it is a systemic action 
on tumor cells.
For a significant period of time, drug therapy against 
squamous-cell oropharyngeal cancer has been applied 
for palliative purposes in the inoperable cases of ad-
vanced, frequently recurrent cancers that are charac-
terized by the presence of distant metastases.
All current regimens of polychemotherapy, in which 
platinum-based or 5-fluorouracil (5 Fu) drugs are used, 
provide an objective response rate of 57–80%; while 
the use of taxanes provides up to 36–40%. the overall 
life expectancy of patients does not increase in both the 
aforementioned cases [4–9]. the low response of tumors 
forces researchers to seek new approaches for systemic 
treatment.
the recent period in the history of anticancer ther-
apy began in the mid-1990s, although its foundations 
were laid as a result of the achievements in fundamen-
tal biology in the last two decades [10]. In those stud-
ies, the molecular mechanisms of regulation of cellular 
proliferation and differentiation were revealed; the lat-reSeArcH ArtIcLeS
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ter enabled the development of drugs acting in a com-
pletely novel way. [11].
In contrast to classic cytostatic drugs, whose action 
is based on disturbing the cell cycle, the drugs for tar-
geted therapy affect only particular molecular targets, 
thereby blocking the earlier stages of carcinogenesis. 
there are drugs of the above-mentioned type that can 
be applied for the treatment of squamous-cell oropha-
ryngeal cancer [2, 10, 12–14].
the main target in the case of SccHn is the epi-
dermal growth factor receptor (eGFr). the hyperex-
pression of epidermal growth factor receptors is noted 
in approximately 90–100% of cases of squamous-cell 
oropharyngeal cancer and is associated with the worst 
prognosis of the disease, a low differentiation of the tu-
mor, and a decrease in the total and recurrence-free 
survival rates [15–17].
In 2004, three research groups published data in-
dicating that mutations in the eGFr tyrosine kinase 
domain increase the response of tumors to the follow-
ing eGFr tyrosine kinase inhibitors: gefitinib and er-
lotinib [12, 16, 18]. the majority of mutations found 
in the EGFR gene are either deletions in exon 19 (29 
from 56.52% of cases), which lead to the loss of four 
amino-acid residues (leucine, arginine, glutamic acid, 
and alanine) in a protein molecule, or point mutations in 
exon 21 causing the replacement of leucine in position 
858 by arginine (20 from 56.36% of cases) [12]. the pres-
ence of mutations in the EGFR gene is an important 
predictor of the probability of a more favorable out-
come in gefitinib therapy. the high effectiveness of ge-
fitinib was confirmed for the case of non-small cell lung 
cancer with a mutation in the EGFR gene: the objective 
response rate was 84.6% [19–21]. Since hyperexpression 
of eGFrs is observed in more than 80% of malignant 
tumors of the head and neck [22], we began studying 
the effectiveness of combined cisplatin, 5-fluorourac-
ile and gefitinib (Iressa) in patients suffering from ad-
vanced (stages III, IV) squamous-cell oropharyngeal 
cancer with a mutation in EGFR.
Gefitinib (Iressa) was one of the first tyrosine kinase 
inhibitors introduced into clinical practice. According 
to its chemical structure, this drug is a derivative of 
anilinoquinazoline. Gifitinib selectively and reversibly 
binds to the AtP-binding site of the eGFr tyrosine ki-
nase domain, thereby blocking its tyrosine kinase activ-
ity, i.e., its ability to phosphorylate the signal proteins 
found after this site; the latter leads to the inhibition 
of proliferative signals [23, 24]. Gefitinib induces an in-
crease in the level of the cyclin-dependent kinase p27 
inhibitor in the cell, in turn causing a delay of the cell 
cycle in G1. Active studies of gefitinib are being per-
formed within international clinical trials. In the Phase 
II clinical trial, application of gefitinib in 52 patients 
with recurrent/metastatic SccHn allowed to achieve 
an objective response in 10.6% of them and to attain a 
level of disease control in 53%. Half of the patient cohort 
received gefitinib as plan B therapy. thus, the median 
progression-free survival and overall survival were 3.4 
and 8.1 months, respectively. the only clinically signifi-
cant side effect observed was diarrhea [25].
EXPERIMENTAL
For the period from March 2009 to April 2011, 48 pa-
tients (42 men, 6 women) aged 40–75 years, a mean age 
of 57 years, were treated.
the diagram presented in Fig. 1 clearly demonstrates 
that the bulk of the patients are men of working age. 
Oropharyngeal cancer is seven times more common in 
men than in women.
Within the patients, the tumor was distributed as 
follows (Fig. 2): the mouth floor in 8 (17%); the orophar-
ynx in 18 (37%); the laryngopharynx in 12 (25%); the 
mobile part of the tongue in 8 (17%); and the retromolar 
area in 2 (4%). In the diagram, it can be clearly seen that 
oropharyngeal and laryngopharyngeal cancers prevail, 
while cancers of the mobile part of the tongue and of 
the retromolar area are less common.
the area of tumor involvement before the beginning 
of therapy was assessed by clinical examination of the 
lesion area, along with computed tomography and ul-
trasonic examination of regional lymph nodes. 
Prior to therapy, the biological profile of the tumor, 
i.e. the expression of epidermal growth factor receptors 
and the presence of mutations in the EGFR gene, was 
determined in all patients. Mutations in the EGFR gene 
were revealed by polymerase chain reaction (Pcr), and 
the expression of eGFrs was ascertained via the im-
munohistochemical method. Allele-specific Pcr with 
primers specific to the L858r mutation in the EGFR 
gene was carried out on the DnA from paraffin blocks 
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Fig. 1. Distribution of patients with oropharyngeal cancer 
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with an established tumor. the wild-type EGFR gene 
undergoes amplification, accompanied by an increase 
in Ct by 7–10 cycles under the same conditions, thus 
enabling the above-mentioned gene to be distinguished 
from the mutant.
naive patients suffering from locally advanced sq-
uamous-cell oropharyngeal cancer (stages III, IV) were 
randomly divided into two groups:
the  first  group  (studied)  received  cisplatin 
(100 mg/m2, via intravenous administration, on the 
first day), 5-fluorouracil (500 mg/m2, via intravenous 
administration, from the first to the fifth day) (four 
cycles with intervals of 21 days); and gefitinib (Iressa) 
(250 mg per os, daily, for 16 weeks).
the  second  group  (control)  received  cisplatin 
(100 mg/m2, via intravenous administration, on the 
first day) and 5-fluorouracil (500 mg/m2, via intrave-
nous administration, from the first to the fifth day) 
(four cycles with intervals of 21 days).
After four cycles, the tumor response was assessed 
clinically and in accordance with the recISt criteria.
In the second stage of complex therapy, the patients 
in whom complete resorption of the tumor was achieved 
were treated with radiation therapy in accordance with 
the radical program: the primary tumor was irradiat-
ed at a total dose of 60–70 Gy, and the regional lymph 
nodes – at a total dose of 30–40 Gy. the patients with 
partial regression and stabilization of the tumor process 
underwent preoperational radiation therapy at a total 
dose of 30–40 Gy, followed by surgery.
RESULTS AND DISCUSSION
the effect of the therapy was assessed in 44 patients 
who went through a complete course of treatment. For 
four patients (16.7%), it was necessary to interrupt the 
treatment due to the appearance of toxic effects: in two 
(8.3%) of them, nephrotoxicity (stage III-IV) appeared; 
in the other two (8.3%), hematologic toxicity (stage IV) 
was observed. Hyperexpression of eGFrs was revealed 
in all 48 patients (100%). However, mutations in the 
EGFR were found in only three (6.8%).
A comparative analysis of the results of the therapies 
in both groups (Table) revealed that a complete clinical 
regression of the tumor was achieved in seven (33.3%) 
people from the group of 21 examined patients, and a 
mutation in the EGFR gene was found in two (4.5%) of 
those seven; in nine (42.9%) cases, a partial response 
(regression of the tumor of up to 85%) was observed; in 
three (14.3%) patients, stabilization of the tumor proc-
ess (a decrease in the tumor by 18–20%) was detect-
ed; and in two (9.5%) patients, tumor progression was 
noted. In the control group of patients receiving only 
standard chemotherapy, a partial response (regression 
of the tumor of up to 57%) was observed in 13 (56.3%) of 
the 23 patients, while in 10 (43.5%) patients, the tumor 
continued to grow. 
CONCLUSIONS
A significant increase was recorded in the effective-
ness of the therapy in people suffering from oropha-
ryngeal cancer by applying gefitinib, a drug used in 
targeted therapy. the effect of gefitinib is most pro-
nounced when there are mutations in the EGFR gene. 
Comparative analysis of the effectiveness of therapy in patients suffering from squamous-cell carcinoma of the head and 
neck, with and without the application of gefitinib
Group
number 
of 
patients
Objective effect Mutated EGFR
complete 
response
Partial 
response Stabilization Progression Yes no
First (studied) 21  7 (33.3%) 9 (42.9%) 3 (14.3%) 2 (9.5%) 2 (4.5%) 20 (45.5%)
Second (control) 23 _ 13 (56.5%) _ 10 (43.5%) 1 (2.3%) 21 (47.7%)
In total 100% 3 (6.8%) 41 (93.2%)
Mouth floor
Oropharynx
Laryngopharynx
Tongue
Retromolar area
17% 4% 17%
25% 37%
Fig. 2. Distribution of patients with oropharyngeal cancer 
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When therapy including gefitinib was used, the clini-
cal tumor response was achieved in 90.5% of patients, 
which was twice higher than in the case of chemo-
therapy alone, 56.5%; and in 33.3% of cases, the result 
was achieved without surgery. the combination of 
targeted therapy with standard chemotherapy al-
lows to increase the effectiveness of the therapy and 
to improve the prognosis for the disease. the results 
obtained in this work show the significant potential 
held by the application of this therapy scheme in con-
servative stages of treatment (chemoradiation thera-
py) during the early stages of the tumor; owing to this, 
organ-preserving complex treatment of patients suf-
fering from squamous-cell oropharyngeal cancer may 
become possible. clinical studies of the effectiveness 
of targeted drugs (erlotinib, gefitinib, cetuximab), 
applied in combination with chemoradiation therapy 
against squamous-cell carcinoma of the head and neck 
with a mutation in the EGFR gene, continue around 
the world. Altogether, the results of these studies 
will open up new opportunities for the treatment of 
the types of patients detailed above, improving their 
quality of life and enabling the performance of organ-
preserving operations. 
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